United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$273.19 USD
-3.07 (-1.11%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $273.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 561 - 580 ( 590 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Preview of UTHR Presentations at the American Thoracic Society (ATS) International Conference.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
We are assuming coverage with a Buy rating and a $90 price target
Provider: AURIGA USA
Analyst: MCDONALD P
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Missed But Growth Intact and We See Significant Upside From Near-Term Data. Raising Rating to OUTPERFORM from NEUTRAL and FV to $94 from $79
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
FREEDOM-C2 Trial Enrolled with Data Anticipated in September
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Financials Missed But Not Material in our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4 Preview: We Believe Q4 Consensus Is a Bit High; However, Since UTHR Is Trading In-Line, We Anticipate a Small Miss Won''t Be Material. Raising FV to $77 from 72
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2011 Major Value Drivers in Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Financials Beat Due To Strong Product Sales. Raising Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Preview: We Believe Q3 Consensus Is A Bit High. However, Since UTHR Is Trading In-Line, We Anticipate A Small Miss Won?t Be Material.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Financials Beat: Lower Operating Expenses And Strong Adcirca Sales Led To GAAP EPS Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Preview: We Believe Q2 Consensus Is Somewhat High. However, Since UTHR Is Trading In-Line With Comparables, We Don?t Expect A Small Miss To Be Material.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L